Limited time offer! 10% off your first blood test order!
Four-area immunity verification for clinical staff — the full pre-employment infectious disease clearance in one appointment.
or 4 interest-free payments of £44.75 with Klarna
Immunity status panel for healthcare and clinical staff covering hepatitis B, MMR (measles, mumps, rubella), varicella, and tuberculosis (IGRA).
NHS and private healthcare employers require clinical staff to demonstrate immunity against a range of vaccine-preventable and blood-borne diseases before beginning patient-facing roles. This comprehensive immunity screen covers the four areas most commonly assessed in occupational health pre-employment clearance: hepatitis B surface antibody titre (confirming vaccine-induced or naturally acquired immunity), MMR serology (measles IgG, mumps IgG, rubella IgG — confirming protection against the three MMR-vaccine target infections), varicella-zoster IgG (confirming chickenpox immunity, essential given the severe consequences of primary varicella in immunocompromised patients), and tuberculosis (using the IGRA QuantiFERON or T-SPOT test, which detects cell-mediated immune response to Mycobacterium tuberculosis). Results are reported in occupational health format with a GMC-registered physician commentary.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Newly appointed NHS clinical staff in all patient-facing roles
Private hospital and clinic employees requiring occupational health clearance
Overseas healthcare workers registering with the NMC or GMC for UK practice
Agency and locum clinical staff moving between employers
Final-year medical and nursing students requiring clearance before clinical placements
TB IGRA testing (QuantiFERON or T-SPOT) requires fresh venous blood that must be processed within 16 to 24 hours of collection; this panel therefore requires a clinic draw rather than a home or postal blood spot. IGRA detects latent as well as active TB; a positive result requires chest X-ray and specialist TB service referral and does not distinguish current active disease from past exposure. Mumps IgG has reduced sensitivity compared with measles and rubella assays, meaning a borderline result may not reliably confirm protection; some occupational health services default to vaccination for borderline mumps results. Varicella IgG testing has some false negative results in individuals vaccinated rather than naturally infected; a positive history of chickenpox combined with vaccination records is often used alongside serology. Results in 5 to 7 working days due to IGRA processing requirements.
From order to physician-reviewed report in as little as three working days.
IGRA testing requires fresh blood processed within 16 to 24 hours of collection.
Bring vaccination records if available; no fasting required.
Priority processing within 24 to 48 hours of receipt.
GMC physician commentary in 5 to 7 working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportAn IGRA (interferon-gamma release assay) is a blood test that measures the immune system’s T-cell response to Mycobacterium tuberculosis antigens. Two IGRA products are used in UK practice: QuantiFERON-TB Gold Plus (QFT-Plus) and T-SPOT.TB. Both detect cell-mediated immunity indicative of past or current TB infection, including latent TB (where the bacteria are contained but not eliminated). The IGRA has largely replaced the Mantoux tuberculin skin test (TST) for NHS occupational health purposes because it is more specific (it does not cross-react with BCG vaccination), requires only a single blood draw, and does not require a 48 to 72 hour follow-up appointment to read the result.
A positive IGRA result indicates that you have had past exposure to Mycobacterium tuberculosis and your immune system has mounted a response. It does not confirm active TB disease; most positive IGRA results in healthcare workers indicate latent TB infection (LTBI). You will be referred to your local NHS TB service or a specialist respiratory physician for further assessment, including chest X-ray and clinical evaluation. If latent TB is confirmed, preventive antibiotic therapy (typically isoniazid for six months, or a shorter rifampicin-based regimen) is offered and highly effective at preventing progression to active TB.
If your rubella IgG is negative or borderline, you will be offered MMR vaccination by your occupational health department. Non-immune healthcare workers — particularly those with contact with pregnant women or reproductive-age patients — represent a patient safety risk because primary rubella in early pregnancy causes congenital rubella syndrome. MMR vaccination is safe, effective, and produces immunity in over 95 percent of recipients. Female staff of childbearing age should use contraception for one month after MMR vaccination due to the theoretical risk of the live attenuated rubella component.
Hepatitis B immunity following a standard three-dose primary vaccination course is durable in the majority of responders. Most individuals who achieve a surface antibody titre above 100 mIU/mL maintain long-term immunological memory even as the detectable antibody titre wanes over years. NHS occupational health guidance states that a documented adequate response (anti-HBs above 100 mIU/mL) to the primary course does not require routine re-testing for boosters unless the individual has a significant blood-borne virus exposure incident. However, some employers and trusts repeat titre testing periodically; clarify the policy with your occupational health department.
NMC and GMC registration requirements relate to professional fitness to practise rather than specific immunological clearance. However, when applying for NHS jobs or clinical placements, the immunity documentation produced by this panel is formatted to UK occupational health standards and is accepted by NHS trusts and most private healthcare employers. Overseas-qualified practitioners seeking UK registration should also verify whether their home country vaccination records are accepted or whether re-testing is required by their prospective NHS employer.
